BET-BAY 002

BET inhibitor, potent CAS# 1588521-78-1

BET-BAY 002

Catalog No. BCC5510----Order now to get a substantial discount!

Product Name & Size Price Stock
BET-BAY 002: 5mg $552 In Stock
BET-BAY 002: 10mg Please Inquire In Stock
BET-BAY 002: 20mg Please Inquire Please Inquire
BET-BAY 002: 50mg Please Inquire Please Inquire
BET-BAY 002: 100mg Please Inquire Please Inquire
BET-BAY 002: 200mg Please Inquire Please Inquire
BET-BAY 002: 500mg Please Inquire Please Inquire
BET-BAY 002: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of BET-BAY 002

Number of papers citing our products

Chemical structure

BET-BAY 002

3D structure

Chemical Properties of BET-BAY 002

Cas No. 1588521-78-1 SDF Download SDF
PubChem ID 73425805 Appearance Powder
Formula C22H18ClN5O M.Wt 403.86
Type of Compound N/A Storage Desiccate at -20°C
Solubility DMSO : ≥ 50 mg/mL (123.81 mM)
*"≥" means soluble, but saturation unknown.
Chemical Name 2-[[(4R)-6-(4-chlorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1]benzazepin-4-yl]methyl]-5-methyl-1,3,4-oxadiazole
SMILES CC1=NN=C2N1C3=CC=CC=C3C(=CC2CC4=NN=C(O4)C)C5=CC=C(C=C5)Cl
Standard InChIKey AGYIAWHWIUZNSD-INIZCTEOSA-N
Standard InChI InChI=1S/C22H18ClN5O/c1-13-24-27-22-16(12-21-26-25-14(2)29-21)11-19(15-7-9-17(23)10-8-15)18-5-3-4-6-20(18)28(13)22/h3-11,16H,12H2,1-2H3/t16-/m0/s1
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

BET-BAY 002 Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

BET-BAY 002 Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of BET-BAY 002

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 2.4761 mL 12.3805 mL 24.7611 mL 49.5221 mL 61.9026 mL
5 mM 0.4952 mL 2.4761 mL 4.9522 mL 9.9044 mL 12.3805 mL
10 mM 0.2476 mL 1.2381 mL 2.4761 mL 4.9522 mL 6.1903 mL
50 mM 0.0495 mL 0.2476 mL 0.4952 mL 0.9904 mL 1.2381 mL
100 mM 0.0248 mL 0.1238 mL 0.2476 mL 0.4952 mL 0.619 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on BET-BAY 002

BET-BAY 002 is a potent BET inhibitor; shows efficacy in a multiple myeloma model.

Featured Products
New Products
 

References on BET-BAY 002

Corrigendum: Orf Virus 002 Protein Targets Ovine Protein S100A4 and Inhibits NF-kappaB Signaling.[Pubmed:28179903]

Front Microbiol. 2017 Feb 7;8:160.

[This corrects the article on p. 1389 in vol. 7, PMID: 27679610.].

Safety and efficacy of intramuscular human placenta-derived mesenchymal stromal-like cells (cenplacel [PDA-002]) in patients who have a diabetic foot ulcer with peripheral arterial disease.[Pubmed:28133924]

Int Wound J. 2017 Oct;14(5):823-829.

The objective of this study was to examine the safety of cenplacel (PDA-002) in patients with peripheral arterial disease (PAD) and a diabetic foot ulcer (DFU). Cenplacel is a mesenchymal-like cell population derived from full-term human placenta. This phase 1, dose-escalation study investigated cenplacel in diabetic patients with chronic DFUs (Wagner grade 1 or grade 2) and PAD [ankle-brachial index (ABI) >0.5 and /=6 months and 11 had an ABI of 0.7-0.85. No patient met dose-limiting toxicity criteria and no treatment-related serious adverse events were reported. There was preliminary evidence of ulcer healing in seven patients (five complete; two partial) within 3 months of cenplacel treatment, and circulating endothelial cell levels (a biomarker of vascular injury in PAD) were decreased within 1 month. Cenplacel was generally safe and well tolerated in patients with chronic DFUs and PAD. Outcomes from this study informed the doses, endpoints, biomarkers and patient population for an ongoing phase 2 trial.

Early management of sepsis with emphasis on early goal directed therapy: AME evidence series 002.[Pubmed:28275488]

J Thorac Dis. 2017 Feb;9(2):392-405.

Severe sepsis and septic shock are major causes of morbidity and mortality in patients entering the emergency department (ED) or intensive care unit (ICU). Despite substantial efforts to improve patient outcome, treatment of sepsis remains challenging to clinicians. In this context, early goal directed therapy (EGDT) represents an important concept emphasizing both early recognition of sepsis and prompt initiation of a structured treatment algorithm. As part of the AME evidence series on sepsis, we conducted a systematic review of all randomized controlled EGDT trials. Focus was laid on the setting (emergency department versus ICU) where EGDT was carried out. Early recognition of sepsis, through clinical or automated systems for early alert, together with well-timed initiation of the recommended therapy bundles may improve patients' outcome. However, the original "EGDT" protocol by Rivers and coworkers has been largely modified in subsequent trials. Currently, many investigators opt for an "expanded" EGDT (as suggested by the Surviving Sepsis Campaign). Evidence is also presented on the effectiveness of automated systems for early sepsis alert. Early recognition of sepsis and well-timed initiation of the SSC bundle may improve patient outcome.

Alcohol dependence and risk of somatic diseases and mortality: a cohort study in 19 002 men and women attending alcohol treatment.[Pubmed:28225200]

Addiction. 2017 Aug;112(8):1358-1366.

AIMS: To (1) estimate sex-specific risks of a comprehensive spectrum of somatic diseases in alcohol-dependent individuals versus a control population, and in the same population to (2) estimate sex-specific risks of dying from the examined somatic diseases. DESIGN: Register-based matched cohort study. Alcohol-dependent individuals were identified from the Copenhagen Alcohol Cohort. Controls were selected randomly from the Danish Civil Registration System. Information on somatic diseases was obtained from the Danish National Patient Registry and causes of death obtained from the Cause of Death Registry. Cox proportional hazards model was applied to estimate hazard ratios (HRs). SETTING: Denmark. PARTICIPANTS: A total of 19 002 alcohol-dependent individuals and 186 767 controls. MEASUREMENTS: Outcome variables included 11 disease groups and 29 subgroups, defined according to the International Classification of Diseases (ICD). The main predictor variable was diagnosis of alcohol dependence according to ICD. FINDINGS: Alcohol-dependent men and women compared with controls had statistically significantly higher risks of all disease groups and the majority of subgroups when analysed as disease events. HRs were elevated for well-established alcohol-related diseases but also for diseases such as dementia [men, HR = 2.0, 95% confidence interval (CI) = 1.6-2.3; women, HR = 2.4, 95% CI = 1.8-3.2], psoriasis (men, HR = 4.3, 95% CI = 3.5-5.2; women, HR = 5.4, 95% CI = 3.7-7.8) and breast cancer in men (HR = 3.3, 95% CI = 1.6-7.0). Similar results were found when disease groups and subgroups were analysed as causes of death. CONCLUSIONS: Alcohol-dependent men and women have significantly higher risks of a comprehensive spectrum of somatic diseases, both as disease events and as causes of death, relative to individuals from the general population.

Description

BET-BAY 002 is a potent BET inhibitor; shows efficacy in a multiple myeloma model.

Keywords:

BET-BAY 002,1588521-78-1,Natural Products,Bromodomain, buy BET-BAY 002 , BET-BAY 002 supplier , purchase BET-BAY 002 , BET-BAY 002 cost , BET-BAY 002 manufacturer , order BET-BAY 002 , high purity BET-BAY 002

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: